Article Abstract

Intralesional collagenase clostridium histolyticum study provides real-world analysis

Authors: Nora M. Haney, Kenneth J. DeLay, Wayne J. G. Hellstrom


Yang and Bennett’s report (1) offers further support for the use of intralesional collagenase clostridium histolyticum (CCH) to improve both subjective symptoms and objective measures in men with Peyronie’s disease (PD). The study included men who would not have been eligible for the IMPRESS (2) trials, including those with active disease, hourglass configurations, ventral deformities, and no upper limit in initial curvature measurements. CCH therapy is currently contraindicated for patients with ventral plaques and hourglass deformities (3). Even with the inclusion of these men, average penile curvature in Yang and Bennett’s report decreased 32.4% compared to the IMPRESS trials, in which the average curvature decreased 34%, with similar efficacy. The percentage of men who had discernable changes to CCH therapy was 60.8% in the IMPRESS trials, while Yang and Bennett observed that 79.6% of men treated with CCH therapy had responded with a decrease in curvature. These results suggest that intralesional CCH therapy may be applied more broadly to PD patients than it is currently approved for.